In a mouse model of hypertension-accelerated diabetic nephropathy, semaglutide significantly reduced hyperglycemia, hypertension, and proteinuria while significantly improving the severity of glomerulosclerosis and urine/kidney injury molecule-1 (KIM-1) levels [122]. The gene discussed is HAVCR1; the disease is diabetic kidney disease.